Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatmentAlbert Wiegman, Olov Wiklund, Joep C. Defesche et al.|European Heart Journal|2015Cited by 868
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 studyMarina Cuchel, Daniel J. Rader, Emma A. Meagher et al.|The Lancet|2012Cited by 739
Homozigot ailevi hiperkolesterolemi: klinisyenlerin tanıyı ve klinik yönetimi geliştirmelerine yönelik yeni anlayışlar ve rehberlik. Avrupa Ateroskleroz Derneği’nin Ailevi Hiperkolesterolemi Üzerine Uzlaşı Paneli yazılı görüşüMarina Cuchel, M. John Chapman, Éric Bruckert et al.|Unknown|2015Cited by 465
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia PanelRaúl D. Santos, Shizuya Yamashita, Samuel S. Gidding et al.|The Lancet Diabetes & Endocrinology|2016Cited by 418
ANGPTL3 Inhibition in Homozygous Familial HypercholesterolemiaDaniel Gaudet, G. Kees Hovingh, Daniel A. Gipe et al.|New England Journal of Medicine|2017Cited by 329